Segregation of the V804L mutation and S836S polymorphism of exon 14 of the RET gene in an extended kindred with familial medullary thyroid cancer

Clinical Genetics

Volumn 63, Issue 3, 2003, Pages 219-223

  Patocs A ^a   Valkusz, Z ^b   Igaz, P ^a   Balogh, K ^a   Toth M ^a   Varga, I ^a   Rácz, Károly ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Familial medullary thyroid cancer; Molecular analysis; Polymorphism; RET

Indexed keywords

DNA; TYROSINE KINASE RECEPTOR;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; EXON; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; GERM LINE; HETEROZYGOTE; HUMAN; HUNGARY; MALE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FEMALE; HUMANS; HUNGARY; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PEDIGREE; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS; VARIATION (GENETICS);

EID: 0043133692     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2003.00044.x     Document Type: Article

References (29)

1. Simpson NE, Kidd KK, Goodfellow PJ et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature 1987: 328: 528-530.
2. Donis-Keller H, Dou S, Chi D et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993: 2: 851-856.
3. Mulligan LM, Kwok JBJ, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993: 2: 458-460.
4. Mulligan LM, Ponder BAJ. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1995: 80: 1989-1995.
5. Seri M, Celli I, Betsos N, Claudiani F, Camera G, Romeo G. A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. Clin Genet 1997: 51: 86-90.
6. Brandi MI, Gagel RF, Angeli A et al. Guidelines for diagnosis and therapy of MEN Type 1 and type 2. J Clin Endocrinol Metab 2001: 86: 5658-5671.
7. Canchez B, Robledo M, Biarnes J et al. High prevalence of C634Y in the RET protooncogene in MEN 2A families in Spain. J Med Genet 1999: 36: 68-70.
8. Eng C, Smith DP, Mulligan LM et al. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene 1995: 10: 509-513.
9. Boccia LM, Green JS, Joyce C, Eng C, Taylor SAM, Mulligan LM. Mutation of RET codon 768 is associated with the FMTC phenotype. Clin Genet 1997: 51: 81-85.
10. Hofstra RMW, Fattoruso O, Quadro L et al. A novel point mutation in the intracellular domain of the ret protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 1997: 82: 4176-4178.
11. Bolino A, Schuffenecker I, Luo Y et al. RET mutations in exons; 13 and 14 of FMTC patients. Oncogene 1995: 10: 2415-2419.
12. Pigny P, Bauters C, Wemeau J-L et al. A novel 9-base pair duplication in RET exon 8 in familiar medullary thyroid carcinoma. J Clin Endocrinol Metab 1999: 84: 1700-1704.
13. Hofstra RMW, Landsvater RM, Ceccherini I et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994: 367: 375-383.
14. Gimm O, Marsh DJ, Andrew SD et al. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997: 82: 3902-3904.
15. Fink M, Weinhausel A, Niederle B, Haas OA. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. Int J Cancer 1996: 69: 312-316.
16. Fattoruso O, Quadro L, Libroia A et al. A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Hum Mut 1998: 00: S167-S171.
17. Heptulla RA, Schwartz RP, Bale AE, Flynn S, Genel M. Familial medullary thyroid carcinoma: presymptomatic diagnosis and management in children. J Pediatr 1999: 135: 327-331.
18. Frohnauer MK, Decker RA. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? Surgery 2000: 128: 1052-1058.
19. Feldmann GL, Edmonds MW, Ainsworth PJ et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-ATG) mutation. Surgery 2000: 128: 93-98.
20. Machens A, Gimm O, Hinze R, Höppner W, Boehm BO, Dralle H. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. J Clin Endocrinol Metab 2001: 86: 1104-1109.
21. Klein I, Ésik O, Homolya V, Szeri F, Váradi A. Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary. J Endocrinol 2001: 170: 661-666.
22. Pasini A, Geneste O, Legrand P et al. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain. Oncogene 1997: 15: 393-402.
23. Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET. from neoplasia to neurogenesis. J Med Genet 2000: 37: 817-827.
24. Gimm O, Neuberg DS, Marsh DJ et al. Over-representation of a germline Ret sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. Oncogene 1999: 18: 1369-1373.
25. Griseri P, Sancandi M, Patrone G et al. A single-nucleotide polymorphic variant of the RET proto-oncogene is under-represented in sporadic Hirschsprung disease. Eur J Hum Genet 2000: 8: 721-724.
26. Ruiz A, Antinolo G, Fernandez RM, Eng C, Marcos I, Borrego S. Germline sequence variant S836S of the RET proto-oncogene is associated with low level predisposition to sporadic medullary thyroid carcinoma in the Spanish population. Clin Endocrinol 2001: 55: 399-402.
27. Berndt I, Reuter M, Saller B et al. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 1998: 83: 770-774.
28. Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 1999: 281: 1587-1588.
29. Ponder BAJ. The phenotype associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res (Suppl.) 1999: 59: 1736-1742.